AbbVie Delivers 400% Returns Beating The S&P 500 by 139%
Market Intelligence Analysis
AI-Powered 70% FREE-ANALYSIS-RULE-BASED-ANALYSISFinancial market analysis indicating bearish sentiment based on current trends.
Article Context
Ten years ago, AbbVie (NYSE:ABBV) was a one-drug story. Humira, the world’s best-selling medicine, threw off the cash that funded everything else. Bears had been warning about its U.S. patent cliff for years, and when biosimilars finally hit in 2023, the drug went into freefall. Humira sales dropped to just $688 million in Q1 2026, ... AbbVie Delivers 400% Returns Beating The S&P 500 by 139%
AI Breakdown
Summary
Financial market analysis indicating bearish sentiment based on current trends.
Time Horizon
Short Term
Analysis and insights provided by AnalystMarkets AI.